- Conditions
- Metrorrhagia, Menorrhagia, Leiomyoma, Adenomyosis, Pelvic Pain, Endometriosis, Pelvic Inflammatory Disease
- Interventions
- Laparoscopic hysterectomy, Abdominal hysterectomy
- Procedure
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 80 Years · Female only
- Enrollment
- 100 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Dallas, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1393–1416
of 13,796
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Surgery
- Interventions
- PSI Rev 1.X, PSI Rev 2.X
- Device
- Lead sponsor
- Masimo Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Contraception
- Interventions
- Norethindrone acetate/ethinyl estradiol
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 1,683 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2008
- U.S. locations
- 66
- States / cities
- Phoenix, Arizona • Tempe, Arizona • Tucson, Arizona + 52 more
- Conditions
- Obesity or Overweight
- Interventions
- AZD5004, Placebo
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 310 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 30
- States / cities
- Chandler, Arizona • Huntington Park, California • La Mesa, California + 27 more
- Conditions
- HIV Infections
- Interventions
- GW810781
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2003
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Diego, California + 18 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Placebo, Linagliptin
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,991 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 197
- States / cities
- Huntsville, Alabama • Scottsboro, Alabama • Tuscumbia, Alabama + 150 more
- Conditions
- Cardiovascular Diseases, Hypertension, Postmenopausal, Overweight or Obese
- Interventions
- Exercise
- Behavioral
- Lead sponsor
- Pennington Biomedical Research Center
- Other
- Eligibility
- 45 Years to 75 Years · Female only
- Enrollment
- 464 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 2
- States / cities
- Dallas, Texas
- Conditions
- Breast Cancer
- Interventions
- Placebo, GLSI-100
- Biological
- Lead sponsor
- Greenwich LifeSciences, Inc.
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 2,250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2031
- U.S. locations
- 51
- States / cities
- Mobile, Alabama • Goodyear, Arizona • Tucson, Arizona + 44 more
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pembrolizumab, Belzutifan, Pembrolizumab/Quavonlimab, Lenvatinib
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 28 more
- Conditions
- Oesophagitis, Eosinophilic
- Interventions
- mepolizumab
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 84 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 20
- States / cities
- Birmingham, Alabama • San Diego, California • Tampa, Florida + 16 more
- Conditions
- Gastroesophageal Cancer, Immune Checkpoint Inhibition
- Interventions
- Nivolumab, Relatlimab
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 3
- States / cities
- Baltimore, Maryland • Pittsburgh, Pennsylvania • Dallas, Texas
- Conditions
- Transfusion-dependent Alpha-Thalassemia, Transfusion-dependent Beta-Thalassemia
- Interventions
- Mitapivat Matched Placebo, Mitapivat
- Drug
- Lead sponsor
- Agios Pharmaceuticals, Inc.
- Industry
- Eligibility
- 1 Year to 17 Years
- Enrollment
- 54 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 4
- States / cities
- Atlanta, Georgia • New York, New York • Philadelphia, Pennsylvania + 1 more
- Conditions
- Fibrillation, Atrial
- Interventions
- omega-3-acid ethyl esters, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 663 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 178
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 149 more
- Conditions
- Coronary Artery Disease, Coronary Artery Bypass Graft (CABG)
- Interventions
- Hyperpolarized 13C Pyruvate Magnetic Resonance Imaging (HP-13C MRI), [¹⁸F]Fluorodeoxyglucose Positron Emission Tomography (FDG-PET), SPECT MPI (Single Photon Emission Computed Tomography Myocardial Perfusion Imaging)
- Diagnostic Test
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 20 Years to 80 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma
- Interventions
- ALN-BCAT, Pembrolizumab
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 16
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 12 more
- Conditions
- Obesity, Overweight
- Interventions
- Maridebart cafraglutide
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Montclair, California • Daytona Beach, Florida + 6 more
- Conditions
- Depressive Disorder, Major
- Interventions
- Vortioxetine, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 469 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 61
- States / cities
- Little Rock, Arkansas • Carson, California • Cerritos, California + 58 more
- Conditions
- Bladder, Neurogenic
- Interventions
- tamsulosin hydrochloride
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 2 Years to 16 Years
- Enrollment
- 143 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 19
- States / cities
- Birmingham, Alabama • Los Angeles, California • Jacksonville, Florida + 16 more
- Conditions
- Cardiac Disease
- Interventions
- Medical/Phenotype Data Collection Procedures & Data to be Collected
- Other
- Lead sponsor
- Methodist Health System
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Bipolar Disorder, Substance Use Disorder
- Interventions
- Icariin
- Drug
- Lead sponsor
- University of Texas Southwestern Medical Center
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Dallas, Texas
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Albiglutide (GSK716155) or exenatide
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 361 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 158
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 142 more
- Conditions
- Sickle Cell Anemia
- Interventions
- Hydroxyurea
- Drug
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 24 Months to 18 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 14
- States / cities
- Birmingham, Alabama • Washington D.C., District of Columbia • Miami, Florida + 9 more
- Conditions
- Cutaneous Squamous Cell Carcinoma (CSCC)
- Interventions
- Cemiplimab, Standard of care
- Drug · Procedure
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 48
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 44 more
- Conditions
- Cervical Dystonia
- Interventions
- Botulinum toxin type A, Placebo
- Biological · Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 116 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 18
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 14 more